# Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients

> **NCT07505160** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 35 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Lisafotoclax
- **DRUG:** Decitabine
- **DRUG:** Homoharringtonine

## Key facts

- **NCT ID:** NCT07505160
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-03
- **Final completion:** 2029-03
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505160, "Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07505160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*